Human Microbiome Sequencing Market Unlocking the Microbiome,Decoding Our Inner World 2024-2031

Human Microbiome Sequencing Market
Human Microbiome Sequencing Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

Market Synopsis-
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Human Microbiome Sequencing Market by (Product Type (Kits And Assays, Instruments, And Software), Technology (Sequencing By Synthesis, Sequencing By Ligation And Other Next-Generation Sequencing Technologies), Traditional Sequencing Technologies (Pyrosequencing And Sanger Sequencing) And Other Sequencing Technology.

Application (Disease Diagnosis (Gastrointestinal Diseases, Metabolic Diseases, Oncology, Infectious Diseases, Neurological Diseases And Other Diseases), Drug Discovery, Consumer Wellness, Omics Analysis (Genome Analysis, Metabolome Analysis, Transcriptome Analysis And Other Omics Analysis) And Other Application), End-User (Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, And Other End Users) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

The global human microbiome sequencing market is estimated to exhibit a CAGR of 20.31% during the forecast period.

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1380

The Human Microbiome Unveiled: A Booming Market for Sequencing
The human body harbors a vast and diverse community of microorganisms known as the microbiome. This ecosystem, composed primarily of bacteria but also including fungi, viruses, and bacteriophages, outnumbers human cells by ten to one and contributes significantly to our overall weight.

Unlocking the secrets of this microbial world is driving the human microbiome sequencing market. Advancements in next-generation sequencing (NGS) technology allow scientists to analyze the microbiome's composition with greater precision. This, coupled with the growing applications of microbiome research in fields like proteomics, metabolomics, and genomics, is creating significant market momentum.

Furthermore, the potential of microbiome-based therapies holds immense promise. Researchers are increasingly exploring the human microbiome as a target for developing novel treatments.

Beyond therapy, human microbiome sequencing is proving valuable for early disease diagnosis and detection. Additionally, declining sequencing costs are making this technology more accessible, further propelling market growth.
Fueled by increased research funding, collaborations between institutions, and the growing body of research on fecal microbiota, the demand for human microbiome sequencing is expected to rise steadily.

The global focus on genetic research, with its inherent connection to the microbiome, is another key driver propelling this market forward. In essence, the human microbiome sequencing market is flourishing due to the convergence of scientific advancements, therapeutic potential, and growing interest in preventative healthcare.

List of Prominent Players in the Human Microbiome Sequencing Market:
• Oxford Nanopore Technologies, Inc.
• Pacific Biosciences of California, Inc.
• QIAGEN N.V.
• Second Genome, Inc.
• Thermo Fisher Scientific Inc.
• Viome, Inc.
• CosmosID
• Leucine Rich Bio Pvt. Ltd.
• Microba
• Microbiome Insights Inc.
• Molzym GmbH & Co. KG
• Baseclear B.V.
• Beijing Genomics Institute (BGI) Genomics Co., Ltd
• Charles River Laboratories International Inc.
• Clinical Microbiomics A/S
• Eurofins Scientific SE
• GENEWIZ, Inc.
• Illumina, Inc.
• Novogene Corporation
• OraSure Technologies, Inc.

Market Dynamics:
Drivers-
The human gut flora significantly enhances the efficacy of pharmaceuticals. Studies have shown that the right microbial balance in the human body aids in treating various diseases. This link between particular disease states and bacteria may present new prospects for medication development (or vaccine manufacturers). Microbes are abundant suppliers of enzymes, making them useful for various therapeutic purposes,

including the search for innovative treatments. With several small, innovative players operating in the market, there are numerous high-growth opportunities for critical stakeholders to acquire companies so that microbiomes can be studied in the hope of discovering new drugs and drug targets for a variety of indications, including obesity, liver disorders, diabetes, and metabolic disorders. Strategic alliances and collaborations are a top priority for many market leaders as they work to expand their product pipelines through efficient research and development methods.

Challenges:
Probiotics have not received FDA approval as a live biotherapeutic product (a biological product, other than a vaccine, that includes living organisms and is used to treat or prevent human illness.). Probiotic-containing foods that are FDA-regulated, including dietary supplements, are nevertheless marketed legally even if they cannot be used to treat, prevent, or alleviate any illnesses. The FDA is thinking about modifying how it describes probiotics.

There can be a separate or brand-new set of regulatory obstacles for genetically engineered microorganisms. Additionally, parallel control groups of healthy individuals must be compared for the present methods for identifying microbial indicators for diagnostic purposes to be effective. It can be difficult to determine which microbe is most suited for a certain application, making it difficult to choose the proper microbial chassis for a microbiota-based treatment.

Regional Trends:
North America currently holds a dominant position in the human microbiome sequencing market due to the region's robust healthcare infrastructure, growing investment from major companies in developing cutting-edge devices, drug development processes, and research activities. The region's dominance is also related to improvements in next-generation sequencing and the rising prevalence of lifestyle problems.

For instance, one prominent American company, Illumina Inc., claims that developing next-generation sequencing has made it possible for several high-profile collaborative projects, like the Human Microbiome Project and MetaHIT. These initiatives have used Next Generation Sequencing as their primary instrument to publish a wide range of data on the human microbiome. The Asia Pacific is anticipated to expand during the projection period because more institutions are opening up in related sectors and the microbiome.

The rising prevalence of lifestyle illnesses, increased awareness of preventative healthcare, financing for microbiome research, and the rising number of microbiome research & clinical activities are propelling the growth of the regional market.

Key Developments: https://www.insightaceanalytic.com/enquiry-before-buying/1380

Recent Developments:
• In September 2021, PhenoBiome announced that its first human gut microbiome assay would be available through Genetic Direction, a Dallas-based distributor of genetics-based health management solutions. Clinical Enterprise, Inc., a Eurofins Scientific subsidiary, will perform the assays in its CLIA- and CAP-certified laboratory.

• In July 2021, Seres Therapeutics Inc. and Nestlé Health Science agreed to collaborate on the commercialization of SER-109, an experimental oral microbiome treatment for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If it is approved, SER-109 will be the first FDA-approved microbiome treatment.

Segmentation of Human Microbiome Sequencing Market-
By Product Type
• Kits and Assays
• Instruments
• Software

By Technology
• Next-Generation Sequencing
o Sequencing by Synthesis
o Sequencing by Ligation
o Other Next-Generation Sequencing Technologies
• Traditional Sequencing Technologies
o Pyrosequencing
o Sanger Sequencing
• Other Sequencing Technology

By Application
• Disease Diagnoses
o Gastrointestinal Diseases
o Metabolic Diseases
o Oncology
o Infectious Diseases
o Neurological Diseases
o Other Diseases
• Drug Discovery
• Consumer Wellness
• Omics Analysis
o Genome Analysis
o Metabolome Analysis
o Transcriptome Analysis
o Other Omics Analysis
• Other Application

By End User
• Research and Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Other End Users

By Region-
• North America-
o US
o Canada
o Mexico
• Europe-
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific-
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific
• Latin America-
o Brazil
o Argentina
o Rest of Latin America
• Middle East & Africa-
o GCC Countries
o South Africa
o Rest of the Middle East and Africa

For Information: https://www.insightaceanalytic.com/customisation/1380

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.